JP MORGAN/CALL/VERTEX PHARMACEUTICALS/350/0.1/17.01.25 | Market Closed - Börse Stuttgart 10:23:43 2024-07-16 am EDT | ||
| 14.41 EUR | +1.55% |
|
| Current month | +11.36% | ||
| 1 month | +5.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 14.41 | +1.55% |
| 24-07-15 | 14.19 | -1.46% |
| 24-07-12 | 14.4 | +1.12% |
| 24-07-11 | 14.24 | +2.23% |
| 24-07-10 | 13.93 | +2.80% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 10:23 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL09PZ |
| ISIN | DE000JL09PZ9 |
| Date issued | 2023-04-12 |
| Strike | 350 $ |
| Maturity | 2025-01-17 (185 Days) |
| Parity | 10 : 1 |
| Emission price | 5.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.5 € |
|---|---|
| Lowest since issue | 5.31 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Warrants
- Warrant
